ArticleJournal of clinical hypertension (Greenwich, Conn.)2025
Impact of COVID-19 Infection on Blood Pressure Variability and Cardiovascular Outcomes in Hypertensive Patients After Complete Liberalization of Epidemic Control in China.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of COVID-19 Infection on Blood Pressure Variability and Cardiovascular Outcomes in Hypertensive Patients After Complete Liberalization of Epidemic Control in China.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This retrospective cohort study assessed the effect of COVID-19 infection on blood pressure variability (BPV) and cardiovascular outcomes in hypertensive patients using 24-h ambulatory blood pressure monitoring and structural equation modeling (SEM). Among 318 patients followed for 2 years, those with infection and poor prognosis showed the most abnormal hemodynamic patterns, including markedly elevated nocturnal SBP load (70.0% vs. 50.1%), higher ARVDBP (9.8% vs. 8.2%), wider pulse pressure (60.9 mmHg), and lower time in target range (30.9% vs. 74.7%, p < 0.001). Cox regression identified infection status, nocturnal BP load, and BP variability as major risk factors, while multivariate models confirmed 11 independent predictors. Neither diabetes nor antihypertensive medication class modified these associations. SEM demonstrated that infection influenced prognosis indirectly through elevated nighttime BP level, load, and variability (indirect effect β = 0.098, p < 0.001). Mechanistically, infection-driven endothelial dysfunction, microthrombotic activation, and autonomic dysregulation, rather than prolonged inactivity, likely underlie the nocturnal amplification of BP instability. These findings support the need for individualized hypertension management during and after infection, focusing on renin-angiotensin system balance, continuation of ACEI/ARB therapy, nighttime dosing of long-acting agents, and circadian BP monitoring to mitigate long-term cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.